by Alex Kadhim
Researchers from Siriraj Hospital, Mahidol University in Thailand demonstrated that haploidentical hematopoietic stem cell transplantation (haplo-HSCT), combined with post-transplant...
by Alex Kadhim
Researchers from Massachusetts General Hospital and collaborating institutions conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of...
by Alex Kadhim
In a recent study, researchers from the University of California, San Francisco, have demonstrated that high exposure to melphalan significantly increases the risk of graft-versus-host disease...
by Alex Kadhim
In a recent study published in The Journal of Immunology, researchers from Ohio State University have demonstrated that inhibition of dihydroorotate dehydrogenase (DHODH) selectively modulates T...
by Blood Advances
Phase II evidence supports the use of post-transplant cyclophosphamide (PTCy) as prophylaxis against acute graft-versus-host disease (aGVHD) in patients undergoing hematopoietic cell...
by Blood Advances
Study data suggest donor age and HLA status influence outcomes in older patients receiving post-transplant cyclophosphamide as graft-versus-host disease prophylaxis following hematopoietic cell...